article thumbnail

First-in-class phosphate absorption inhibitor approved by FDA

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. XPHOZAH is expected to be available to eligible patients in the US in November 2023.

FDA 108
article thumbnail

FDA approves first treatment for geographic atrophy

European Pharmaceutical Review

SYFOVRE (pegcetacoplan injection) is the first and only treatment approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA), a leading cause of blindness. SYFOVRE is expected to be available by the beginning of March 2023. GA is an advanced form of age-related macular degeneration (AMD).

FDA 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Insights+: The US FDA New Drug Approvals in January 2023

PharmaShots

Shots: The US FDA approved 8 NDAs and 1 BLA in January 2023, leading to treatments for patients and advances in the healthcare industry. insurance coverage & co-pay programs. At the same time, PAP offers Leqembi at no cost for eligible uninsured & underinsured patients, incl.

FDA 40
article thumbnail

Xdemvy side effects and how to avoid them

The Checkup by Singlecare

Food and Drug Administration (FDA) in July of 2023 to treat Demodex blepharitis (inflammation of the eyelids). Manufactured by Tarsus Pharmaceuticals, it is the only FDA-approved treatment that targets and kills Demodex mites that cause Demodex blepharitis. Like all medications, side effects may occur when taking Xdemvy.

article thumbnail

Insights+: EMA Marketing Authorization of New Drugs in May 2023

PharmaShots

The therapy is currently under the US FDA's review 3. from completion of or are refractory to 1L chemoimmunotherapy The approval was based on the P-III trial (TRANSFORM) evaluating Breyanzi vs SoC in 184 patients which showed improved EFS with a manageable and well-established safety profile, m-EFS (10.1 vs 2.3mos.) of treatment, incl.

article thumbnail

Jardiance for heart failure: How it works, effectiveness & more

The Checkup by Singlecare

The drug and its fellow SGLT2 inhibitors, Farxiga (dapagliflozin), Invokana (canagliflozin), Steglatro (ertugliflozin), and Brenzavvy (bexagliflozin), are approved by the Food and Drug Administration (FDA) for treatment of Type 2 diabetes. But unlike the other drugs, Jardiance has evidence to support its different uses.

article thumbnail

Mounjaro interactions to avoid

The Checkup by Singlecare

In fact, in late 2023, its manufacturer, Eli Lilly, released another brand form of tirzepatide, Zepbound , with Food and Drug Administration (FDA) approval for weight loss. Still, according to the FDA’s boxed warning , anyone with a history of MTC or a personal or family history of MEN2 should avoid it.